Meeting
2024 ASCO Gastrointestinal Cancers Symposium
ZSAB-TOP: A phase 2 trial of tislelizumab (TIS) and ociperlimab (OCI) combined with gemcitabine and cisplatin (GemCis) as the first-line treatment for advanced biliary tract cancer (BTC).
Authors
Jia Fan
Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, China
Jia Fan , Jian Zhou , Guoming Shi , Xiaoyong Huang , Liang Ma , Jun-Ye Wang , Qiang Gao , Shuangjian Qiu , Huichuan Sun , Yinghong Shi , Xiao-Wu Huang , Xiaoying Wang , Yong Yi , Xiaodong Zhu , Cheng Huang , Zhenbin Ding , Yi Chen , Yi-Feng He , Yinghao Shen , Qiman Sun
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05023109
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 475)
DOI
10.1200/JCO.2024.42.3_suppl.475
Abstract #
475
Poster Bd #
B20
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 2, open-label, safety and efficacy study of telotristat ethyl plus first-line chemotherapy in patients with advanced biliary tract cancer.
First Author: Richard D. Kim
Poster
2024 ASCO Annual Meeting
QUIC: Phase 2 study of gemcitabine, cisplatin, quemliclustat (AB680), and zimberelimab (AB122) during first-line treatment of advanced biliary tract cancers (BTC)—Big Ten Cancer Research Consortium study BTCRC-GI22-564.
First Author: John Ebben
Poster
2019 ASCO Annual Meeting
NUC-1031 in combination with cisplatin for first-line treatment of advanced biliary tract cancer.
First Author: Jennifer J. Knox
Poster
2024 ASCO Annual Meeting
The safety and efficacy of ivonescimab in combination with chemotherapy as first-line treatment for advanced biliary tract cancer.
First Author: Jieer Ying